RxDoctor Payments Data

Shalender Bhasin, MD

Endocrinology, Diabetes & Metabolism · Weston, MANPI 1134138274

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $18,050 of the $27,449 with a category attached, or 65.8%. Besins Healthcare Ireland Limited accounts for 85.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $23,500 and has fallen 83.9% since, to $3,788 in 2024.

$27,449in general payments, 2019–2025

Across 16 payments — averaging $1715.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Besins Healthcare Ireland Limited$23K
  • Eli Lilly$4K
  • Novo Nordisk$161
$253,632in research payments, 2019–2025

Across 9 payments — averaging $28,181 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$253K
  • AbbVie$765

What the payments were for

  • Consulting fees$9,23834%
  • Travel & lodging$18,05066%
  • Education$1611%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Besins Healthcare Ireland Limited6$23,500
Eli Lilly5$3,788
Novo Nordisk5$161

How this compares

$27,449 in reported general payments places this provider in the 85th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,446
Medicare patients
29
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Testosterone Cypionate98$3,307

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Weston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →